A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2015 by Rockefeller University
Weill Medical College of Cornell University
Brigham and Women's Hospital
University of Cologne
Information provided by (Responsible Party):
Rockefeller University
ClinicalTrials.gov Identifier:
First received: December 17, 2013
Last updated: April 20, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2016
  Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)